Pasithea Therapeutics is dedicated to advancing therapies for central nervous system (CNS) disorders through innovative research and development. The company is focused on creating new molecular entities aimed at treating conditions such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, Neurofibromatosis type 1, and Noonan syndrome. With a team of experts in neuroscience and pharmacology, Pasithea is committed to addressing the unmet medical needs associated with these challenging diseases.

The company's research and development efforts are centered on building a robust portfolio of proprietary drug candidates that specifically target neuroinflammatory disorders of the CNS. This strategic focus on neuroinflammation highlights Pasithea's commitment to understanding the underlying mechanisms of CNS diseases and developing effective therapeutic solutions. Through their innovative approach, Pasithea aims to contribute significantly to the treatment landscape for patients suffering from these debilitating conditions.

United States

Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders. We leverage our expertise in the fields of neuroscience, medicinal chemistry, and translational medicine to develop new molecular entities that target the pathophysiology underlying such diseases with the goal of bringing life-changing therapies to patients.

Central Nervous System (CNS)

Nervous System Diseases

Pasithea Therapeutics

Cancer

Solid tumor/s

<p class="font_8">PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Blocking the phosphorylation of ERK can lead to cell death and inhibition of tumor growth. Existing FDA approved MEK inhibitors are marketed for a range of diseases, including certain cancers and neurofibromatosis type 1 (NF1). We believe these MEK inhibitors suffer from certain limitations, including known toxicities. Unlike current FDA approved MEK inhibitors, PAS-004 is macrocyclic, which we believe may lead to improved pharmacokinetic and safety (tolerability) profiles. Cyclization offers rigidity for stronger binding with drug target receptors. PAS-004 was designed to provide a longer half-life with what we believe is a better therapeutic window. Further, we believe the potency and safety profile that PAS-004 has demonstrated in preclinical studies may also lead to stronger and more durable response rates and efficacy, as well as better dosing schedules.&nbsp;PAS-004 has been tested in a range of mouse models of various diseases and has completed preclinical testing and animal toxicology studies. Additionally, PAS-004 has received orphan-drug designation from the FDA for the treatment of NF1.</p>

Pasithea Therapeutics

Company Details